Evaluating mAbs binding abilities to Omicron subvariant RBDs: implications for selecting effective mAb therapies.

bebtelovimab (LY-CoV1404) - AbCellera, Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/38591159

Bangyu Liu; Bolin Tang; Danyang Xiong; Lili Duan; Song Luo; Xiaoyu Zhao

Apr 9, 2024